Data published in The Journal for ImmunoTherapy of Cancer show ClearNote Health’s epigenomic platform may provide a novel tissue-free, liquid biopsy-based approach for prediction and monitoring of immunotherapy response for non-small cell lung cancer patients.
Researchers at Baylor College of Medicine and collaborating institutions developed a kinase inhibitor pulldown assay that can optimally enrich and quantify the small amounts of kinases present in biopsy samples in combination with mass-spectrometry techniques.
A study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into glioblastoma neuron mimicry and potential therapies to prevent treatment resistance.
FDA approved Keytruda (pembrolizumab) with chemoradiotherapy for patients with FIGO 2014 stage 3-4A cervical cancer.
The United States Patent and Trademark Office, or USPTO issued U.S. Patent No. US 11,873,348 covering ATOR-4066, a Neo-X-Prime next generation bispecific antibody targeting CD40 and CEACAM5, in the treatment of cancer.
When Naoto T. Ueno left MD Anderson to become director of the University of Hawaiʻi Cancer Center, he took one of the most challenging jobs in oncology.
As Joe Simone said, “Once you have seen one cancer center, you have seen one cancer center.” This statement is certainly true of the University of Hawaiʻi Cancer Center (UHCC).
Roy S. Herbst, deputy director of Yale Cancer Center and Smilow Cancer Hospital and assistant dean for translational research at Yale School of Medicine, was elected to the Friends of Cancer Research Board of Directors.
Mohandas Narla, head of the laboratory of red cell physiology at New York Blood Center Enterprises, began his term as president of the American Society of Hematology. He will serve a year-long term through December 2024.
The largest professional societies representing radiation oncology physicians in the United States announced a partnership with the goal of reforming radiation oncology Medicare payments to expand and enhance access to high quality care for people with cancer.
